News
Competition in the NHS: ‘Payment by Results’
17 August 2010
Jon Sussex, Deputy Director of the OHE, researches incentives and competition in UK health services. In July, he presented findings on ‘Payment by Results’ to the…
Comparing Economic Appraisal Guides in England
10 August 2010
Debate continues about the methods that the UK’s NICE uses in its appraisals of medical technologies, including whether effects beyond the NHS should be considered using…
Limits to Using QALYs in Cancer
3 August 2010
QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for…
Part 2: 2010 Lecture on US Health Reform
27 July 2010
Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care…
Part 1: 2010 Lecture on US Health Reform
20 July 2010
Each year, OHE sponsors an Annual Lecture that examines an important issue in health care. In late June, Dr Alan Garber spoke on US health care…
Estimating US Savings from Biosimilars
13 July 2010
The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually…
EU Approval of Biosimilars
8 July 2010
Biosimilar products in the European Union (EU) must go through a centralised procedure that licenses the product for use in EU Member States. Until experience grows…
Reminder: Willingness-to-Pay Seminar
5 July 2010
Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money? Whose Money? During this OHE Lunchtime Seminar, Prof Peter Zweifel, University of Zurich, will discuss the findings…
Biosimilars’ Price Dynamic in Europe
30 June 2010
Europe already has some experience with the impact of biosimilars on pricing, including a price war in Germany for EPOs. Whether that experience will be repeated,…